Vitamin D analogues and psoriasis

Journal of Clinical Pharmacy and Therapeutics

Volumn 21, Issue 3, 1996, Pages 143-148

  Stewart, D G ^a   Lewis, H M ^a  

^a SELLY OAK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; COLECALCIFEROL; COLECALCIFEROL DERIVATIVE; TACALCITOL;

ARTICLE; CELL PROLIFERATION; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; IMMUNE SYSTEM; INFLAMMATION; KERATINOCYTE; PATHOGENESIS; PSORIASIS; TOPICAL DRUG ADMINISTRATION;

EID: 0029745967     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.1996.tb00013.x     Document Type: Article

References (53)

1. Baker BS, Fry L. (1992) The immunology of psoriasis. British Journal of Dermatology, 126, 1-9.
2. Wright NA, Camplejohn RS, eds. Psoriasis: Cell Proliferation. Churchill Livingstone, Edinburgh.
3. Morimoto S, Yoshikawa K, Kozuka T, et al. (1986) An open study of vitamin D, treatment in psoriasis vulgaris. British Journal of Dermatology, 115, 421-429.
4. 3 for psoriasis: a report of five cases. Calcified Tissue International 38, 119-122.
5. Smith R. (1987) Disorders of the skeleton. In: Oxford Textbook of Medicine, eds Weatherall DJ, Leadingham JGG, Warrell DA. Chapter 17 pp. 4-5, Oxford Medical Publications, Oxford.
6. Malloy PJ, Weisman Y, Feldman D. (1994) Hereditary 1 alpha, 25-dihydroxyvitamin D-resistant rickets resulting from a mutation in the vitamin D receptor deoxyribonucleic acid-binding domain. Journal Clinical Endocrinology and Metabolism, 78(2), 313-316.
7. Van de Kerkhof PCM. (1995) Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. British Journal of Dermatology, 132, 675-682.
8. Braun-Falco O, Plewig G, Wolff HH, Winkelmann RK. (1990) Psoriasis vulgaris. In: Dermatology, pp. 403-437, Springer-Verlag, Berlin.
9. Camp RDR. (1992) Psoriasis. In: Rook Textbook of Dermatology, eds Champion RH, Burton J, Ebling FJG. pp. 1391-1457, Blackwell Scientific Publications, Oxford.
10. Rea JN, Newhouse ML, Halil T. (1976) Skin disease in Lambeth. British Journal of Preventive and Social Medicine, 30, 107-114.
11. Johnson M, Roberts J. (1978) Skin conditions and related need for medical care among persons 1-74 years. US National Health Survey 1971-74. Vital and Health Statistics. Series II, no. 212, pp. 1-72.
12. Watson W, Cann HM, Forber EM, et al. (1972) The genetics of psoriasis. Archives of Dermatology, 105, 197-207.
13. Iselius L, Williams WR. (1984) The mode of inheritance of psoriasis: evidence for a major gene as well as a multifactorial component and its implication for genetic counselling. Human Genetics, 68, 73-76.
14. Russell TJ, Schultes LM, Kirban DJ. (1972) Histocompatibility (HL-A) antigens associated with psoriasis. New England Journal of Medicine, 287, 738-740.
15. White SH, Newcomer VD, Mickey MR, et al. (1972) Disturbance of HLA antigen frequency in psoriasis. New England Journal of Medicine, 287, 740-743.
16. Batchelor JR, Morris PJ. (1977) HLA and disease - joint report. In: Histocompatibility testing, eds Bodmer WF, Batchelor JR, Bodmer JG et al. pp. 205, Munksgaard, Copenhagen.
17. Forber EM, Nall ML, Watson W. (1974) Natural history of psoriasis in 61 twin pairs. Archives of Dermatology, 109, 207-211.
18. Lomholt G, ed. (1963) Psoriasis: Prevalence, Spontaneous Course and Genetics. A Census Study on the Prevalence of Skin Diseases on the Faroe Islands. Gad, Copenhagen.
19. Walsdorfer U, Christopher E, Schroder J.-M. (1983) Methotrexate inhibits polymorphonuclear leucocyte chemotaxis in psoriasis. British Journal of Dermatology, 108, 451-456.
20. Morison WL, Wimberley J, Parish JA, et al. (1983) Abnormal lymphocyte function following long-term PUVA therapy for psoriasis. British Journal of Dermatology, 108, 445-450.
21. Borel JF, Feurer C, Gubler HU, et al. (1976) Biological effects of cyclosporin A: a new anti-lymphocytic agent. Agents Actions, 6, 468-475.
22. Lewis HM. (1994) Therapeutic progress II: treatment of psoriasis. Journal of Clinical Pharmacy and Therapeutics, 19, 223-232.
23. Valdimorrson H, Baker BS, Jonsdottir I, Fry L. (1986) Psoriasis: a disease of abnormal keratinocyte proliferation induced by T-lymphocytes. Immunology Today, 7, 256-259.
24. Grossman RM, Kreuger J, Yourish D, et al. (1989) Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proceedings of the National Academy of Sciences of the United States of America, 86, 6367-6371.
25. Griffiths CEM, Vorhees JJ, Nickoloff BJ. (1989) Characterisation of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin. Modulation by recombinant gamma interferon and tumour necrosis factor. Journal of the American Academy of Dermatology, 20, 617-629.
26. 3. Archives of Dermatology, 123, 1677-1683a.
27. Haussler MR. (1986) Vitamin D receptors: nature and function. Annual Review of Nutrition, 6, 527-562.
28. McDonnell DD, Mangelsdorf DJ, Pike JW, et al. (1987) Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. Science 235, 1214-1217.
29. 3 analogue, stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Archives of Dermatology Research, 282, 164-167.
30. 3 in gynecologic neoplasms. Gynecologic Oncology, 44, 131-136.
31. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcaemia. Endocrinology, 129, 832-837.
32. 3. Endocrinology, 113, 1950-1957.
33. 3 increases intracellular calcium in human keratinocytes. British journal of Dermatology, 120, 21-30.
34. Sharpe GR, Gillespie GL, Greenwell JR. (1990) Changes in intracellular free calcium of human keratinocytes during differentiation and stimulation with EGF. British Journal of Dermatology, 122 (abstract), 269-270.
35. 3 on the transglutaminase activity of transformed mouse epidermal cells in culture. Journal of Dermatology, 16, 7-11.
36. 3 in HL-60 cells. Journal of Biological Chemistry, 265, 2370-2374.
37. Tsoukaz CD, Provvedini DM, Manologas SC. (1984) 1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. Science, 224, 1438-1440.
38. 3 and MC903 on the production of IL-6, γ-IFN and T-lymphocyte proliferation in peripheral blood mononuclear cells. Journal of Bone and Mineral Research, 6 (abstract), 292.
39. 3. Journal of Cellular Biochemistry, 49, 26-31.
40. Lemann J Jr, Gray RW. (1984) Calcitriol, calcium and granulomatous disease. New England Journal of Medicine, 311, 1115-1117.
41. Zhou JY, Norman AW, Lubbert M, et al. (1989) Novel vitamin D analogues that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone mobilisation. Blood 74, 82-93.
42. 3. Japanese Journal of Bone and Mineral Metabolism, 3 (abstract), 74.
43. Smith EL, Pincus SH, Donovan L, et al. (1988) A novel approach for the evaluation and treatment of psoriasis. Journal of the American Academy of Dermatology, 19, 516-528.
44. Holland DB, Wood EJ, Cunliffe WJ, et al. (1988) Effect of 1a-hydroxyvitamin D3 on epidermal keratin in psoriasis. Journal of Investigative Dermatology. 91, 414-418.
45. Czarnetzki BM. (1989) Vitamin D3 in dermatology: a critical appraisal. Dermatologica, 178, 184-188.
46. Binderup L, Kragballe K. (1992) Origin of the use of calcipotriol in psoriasis treatment. Review of Contemporary Pharmacotherapy, 3, 357-365.
47. Verburgh CA, Nieboer C. (1989) Local application of vitamin D derivative MC903 in psoriasis: influence on cellular infiltrate, Langerhans cells and keratinocyte markers. Journal of Investigative Dermatology, 93 (abstract), 310.
48. Tham SN, Lun KC, Cheong WK. (1994) A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. British Journal of Dermatology, 131, 673-677.
49. Cunliffe WJ, Berth-Jones J, Claudy A, et al. (1992) Comparative study of Calcipotriol (MC903) ointment and betamethasone-17-valerate in patients with psoriasis vulgaris. Journal of the American Academy of Dermatology, 26, 736-743.
50. Dwyer C, Chapman RS. (1991) Calcipotriol and hypercalcaemia. Lancet, 338, 764-765.
51. 3 with high activity for inducing epidermal differentiation but decreased hypercalcaemic activity. Journal of Dermatology, 17, 135-142.
52. 3) on cutaneous inflammation, epidermal proliferation and keratinisation in psoriasis: a placebo-controlled, double-blind study. British Journal of Dermatology, 131, 57-63.
53. 3 is a potent modulator of in vivo immunoregulating activity without inducing hypercalcaemia in mice. Endocrinology, 124, 2645-2647.